Business Context and Reporting Period
Company: Mineralys Therapeutics, Inc. (MLYS)
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2026
Reporting Period: Immediate event reporting for transactions executed on June 2, 2026.
The Company entered into two material definitive agreements: a Fourth Amendment to its License Agreement with Tanabe Pharma Corporation regarding the drug lorundrostat, and a new Senior Secured Term Loan Facility.
Key Financial Metrics and Obligations
License Agreement Amendment (Tanabe Pharma):
- Upfront Payment: $200.0 million one-time cash payment to Tanabe upon execution.
- New Milestones: Up to $100.0 million in aggregate commercial milestone payments.
- Remaining Obligations: Up to $255.0 million in commercial milestones upon first commercial sale and annual sales targets; up to $10.0 million for a second indication.
- Royalties: Future royalty payments to Tanabe are terminated.
- Change of Control: New Milestones become immediately payable upon a change of control or asset sale involving U.S. rights.
Senior Secured Term Loan Facility:
- Total Facility Size: Up to $500.0 million.
- Tranche A (Drawn): $100.0 million drawn on June 2, 2026.
- Tranche B (Conditional): $150.0 million, required by April 30, 2027, subject to FDA NDA approval.
- Tranche C (Conditional): $150.0 million, available until December 14, 2028, subject to Tranche B approval and net sales milestones.
- Tranche D (Conditional): $100.0 million, available until June 14, 2029, subject to Tranche C draw and net sales milestones.
- Interest Rate: 3-month SOFR (3.25% floor) + 5.50%.
- Funding Fee: 2.00% of the funding amount per tranche.
- Maturity Date: June 3, 2031.
Liquidity and Margins: The filing text does not provide current cash balances, revenue, profit, or margin data.
Material Changes Versus Prior Period
- Intellectual Property Rights: The license for lorundrostat was amended to be exclusive, worldwide, royalty-free, sublicensable, perpetual, and irrevocable. Diligence obligations to Tanabe were removed.
- Debt Structure: The Company incurred a new $100.0 million immediate debt obligation with potential access to an additional $400.0 million contingent on regulatory and commercial milestones.
- Cash Outflow: Immediate cash outflow of $200.0 million for the Tanabe amendment plus the 2.0% funding fee on the $100.0 million loan tranche.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook:
- The Company expects to finalize a Termination Agreement with Tanabe to assign all licensed intellectual property rights to Mineralys.
- Future funding tranches are contingent on FDA approval of the lorundrostat New Drug Application (NDA) and achievement of net sales milestones.
Risks and Contingencies:
- Regulatory Risk: Tranche B funding is conditional on FDA NDA approval. Failure to meet this condition by September 30, 2027, triggers mandatory repayment of all term loans in four equal payments.
- Financial Covenants: The loan agreement includes a minimum liquidity requirement prior to Tranche B approval and a minimum trailing twelve-month consolidated net product revenue covenant starting in fiscal year 2028.
- Restrictive Covenants: The Company is restricted from incurring additional indebtedness, paying dividends, making equity distributions, or selling assets without lender consent.
- Collateral: Obligations are secured by substantially all Company assets, including intellectual property.
- Forward-Looking Uncertainties: Risks include FDA review delays, clinical trial results, macroeconomic conditions, and the potential failure to reach the proposed Termination Agreement with Tanabe.
Investor Verification Checklist
- Verify the exact cash balance remaining after the $200.0 million Tanabe payment and loan funding fees.
- Confirm the status of the FDA NDA review for lorundrostat, as this dictates the ability to draw the $150.0 million Tranche B.
- Review the full text of the Termination Agreement with Tanabe to confirm the assignment of IP rights.
- Assess the Company's ability to meet the minimum liquidity covenant prior to the Tranche B approval condition.
- Monitor the timeline for the mandatory repayment trigger if Tranche B is not approved by September 30, 2027.